Jump to main content
Jump to site search

Issue 1, 2015
Previous Article Next Article

Cationic azacryptands as selective three-way DNA junction binding agents

Author affiliations

Abstract

DNA damaging agents are among the most powerful anticancer drugs currently in clinical use. As an alternative to irreversible nucleobase damage and DNA strand breaks, the non-covalent stabilization of unusual, non-B DNA structures is currently emerging as a promising way to cause DNA damage with a high level of specificity. One of such non-B DNA structures is the three-way DNA junction: this Y-shaped multi-stranded architecture may act as an impediment to many DNA transactions, being therefore regarded as an invaluable target to create genomic defects that are improperly dealt with by cancer cells only. Herein, we report on a series of cationic azacryptands that make excellent candidates for assessing and harnessing the actual therapeutic potential of three-way DNA junction interacting compounds.

Graphical abstract: Cationic azacryptands as selective three-way DNA junction binding agents

Back to tab navigation

Supplementary files

Publication details

The article was received on 29 Aug 2014, accepted on 15 Oct 2014 and first published on 15 Oct 2014


Article type: Paper
DOI: 10.1039/C4OB01846J
Author version
available:
Download author version (PDF)
Org. Biomol. Chem., 2015,13, 215-222

  •   Request permissions

    Cationic azacryptands as selective three-way DNA junction binding agents

    J. Novotna, A. Laguerre, A. Granzhan, M. Pirrotta, M. Teulade-Fichou and D. Monchaud, Org. Biomol. Chem., 2015, 13, 215
    DOI: 10.1039/C4OB01846J

Search articles by author

Spotlight

Advertisements